Literature DB >> 18852277

Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.

Brenda Edith Chacon-Moreno1, Oliverio Welsh, Norma Cavazos-Rocha, Maria de la Luz Salazar-Cavazos, Hector Gerardo Garza-Lozano, Salvador Said-Fernandez, Jorge Ocampo-Candiani, Lucio Vera-Cabrera.   

Abstract

The efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis was evaluated by applying 25 mg of each drug/kg subcutaneously every 8 h in BALB/c mice infected with N. brasiliensis. A statistically significant difference was observed only with moxifloxacin. A moxifloxacin-trimethoprim-sulfamethoxazole combination was as active as when each compound was used alone.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18852277      PMCID： PMC2612135          DOI： 10.1128/AAC.01023-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Treatment of multiple subcutaneous Nocardia asteroides abscesses with ciprofloxacin and doxycycline.

Authors:  P M Bath; K W Pettingale; J Wade
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

2.  Gatifloxacin and dysglycemia in older adults.

Authors:  Vijay Yadav; Kuldeep Deopujari
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

3.  Two cases of Nocardia asteroides sternotomy infection treated with ofloxacin and a review of other active antimicrobial agents.

Authors:  W W Yew; P C Wong; S Y Kwan; C Y Chan; M S Li
Journal:  J Infect       Date:  1991-11       Impact factor: 6.072

4.  Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.

Authors:  M F Tripodi; L E Adinolfi; A Andreana; G Sarnataro; E Durante Mangoni; M Gambardella; R Casillo; C Farina; R Utili
Journal:  Clin Transplant       Date:  2001-12       Impact factor: 2.863

Review 5.  The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Authors:  G J Alangaden; S A Lerner
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

Review 6.  Mycetoma.

Authors:  Oliverio Welsh; Lucio Vera-Cabrera; Mario Cesar Salinas-Carmona
Journal:  Clin Dermatol       Date:  2007 Mar-Apr       Impact factor: 3.541

7.  In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.

Authors:  Alejandra Daw-Garza; Oliverio Welsh; Salvador Said-Fernández; Hector Gerardo Lozano-Garza; Noemi Waksman de Torres; Norma Cavazos Rocha; Jorge Ocampo-Candiani; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

8.  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Authors:  Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

9.  In vitro activities of new antimicrobials against Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis.

Authors:  Nelly Alejandra Espinoza-González; Oliverio Welsh; Noemi Waksman de Torres; Norma Cavazos-Rocha; Jorge Ocampo-Candiani; Salvador Said-Fernandez; Gerardo Lozano-Garza; Sung-Hak Choi; Lucio Vera-Cabrera
Journal:  Molecules       Date:  2008-01-11       Impact factor: 4.411
View more
  5 in total

1.  In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.

Authors:  Lucio Vera-Cabrera; Mayra Paola Campos-Rivera; Wendy G Escalante-Fuentes; Michael J Pucci; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.

Authors:  Hung-Jen Tang; Wen-Chien Ko; Chi-Chung Chen; Po-Lin Chen; Han Siong Toh; Tzu Chieh Weng; Wen-Liang Yu; Shyh-Ren Chiang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

3.  Nocardia brasiliensis cell wall lipids modulate macrophage and dendritic responses that favor development of experimental actinomycetoma in BALB/c mice.

Authors:  J Humberto Trevino-Villarreal; Lucio Vera-Cabrera; Pedro L Valero-Guillén; Mario C Salinas-Carmona
Journal:  Infect Immun       Date:  2012-07-30       Impact factor: 3.441

Review 4.  Mycetoma medical therapy.

Authors:  Oliverio Welsh; Hail Mater Al-Abdely; Mario Cesar Salinas-Carmona; Ahmed Hassan Fahal
Journal:  PLoS Negl Trop Dis       Date:  2014-10-16

Review 5.  Global burden of human mycetoma: a systematic review and meta-analysis.

Authors:  Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2013-11-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.